China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced a significant ten-year partnership agreement with Wuhan Hesheng Technology Co., Ltd. While the financial specifics of the deal remain undisclosed, the collaboration is poised to enhance both companies’ capabilities in the pharmaceutical sector.
Collaboration Focused on R&D and Production
Under the terms of the agreement, Hesheng will authorize Apeloa to undertake research and development, as well as production for the designated project. This partnership allows Apeloa to leverage the processes and technologies provided by Hesheng, ensuring a streamlined approach to development. Importantly, Apeloa is prohibited from using these processes and technologies to offer services to third parties.
Intellectual Property Rights Retained by Hesheng
Throughout the collaboration, any research and development achievements and related intellectual property rights generated will belong solely to Hesheng. This stipulation emphasizes Hesheng’s commitment to retaining control over its proprietary technologies while fostering innovation through strategic partnership.-Fineline Info & Tech
